Pioglitazone in clinical use is thought to enhance peripheral insulin sensitivity as a diabetes therapeutic agent (47, 48); however, these supportive data also demonstrate direct effects of PPARγ agonists in the functional preservation of β-cells (34). The gene discussed is PPARG; the disease is diabetes mellitus.